Compare Paychex, Inc. (PAYX) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Paychex, Inc. vs Tango Therapeutics Inc. — how do they compare? Paychex, Inc. trades at $109.38 (market cap $38.58B), while Tango Therapeutics Inc. trades at $22.5 (market cap $3.74B). The key difference: Paychex, Inc. is far larger — about 10.3× Tango Therapeutics Inc.'s market cap, and Paychex, Inc. pays a 4.39% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Paychex, Inc. for 56 Days and Tango Therapeutics Inc. for 0 Days on average.
| PAYX | TNGX | |
|---|---|---|
Market Cap | $38.58B | $3.74B |
Volume | 2,721,004 | 3,438,781 |
Sector | Industrials | Health |
52-Week High | $127.54 | $32.90 |
52-Week Low | $85.57 | $7.50 |
Typical Hold Time | 56 Days | 0 Days |
Enterprise Value | $42.26B | $2.76B |
Dividend Yield | 4.39% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Paychex (PAYX) trades at $106.26, up 1.55% today, with a bullish technical signal despite some bearish moving average indicators. The company reported a beat on Q2 2026 EPS of $1.34 versus $1.32 expected, continuing a trend of earnings outperformance. Revenue grew to $5.57B in 2025, with strong profitability margins including a 27.35% net income margin and 47.06% ROE. Recent news highlights dividend sustainability concerns amid a stock price decline, though the company maintains a solid financial position.
The outlook for PAYX is mixed; fundamentals remain robust with consistent earnings beats and high profitability, but investor sentiment is cautious due to valuation concerns and labor market exposure. Near-term price action hinges on Q3 2026 earnings and dividend coverage metrics. Risks include economic sensitivity and competitive pressures, while analyst consensus suggests modest upside to a $111 price target.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Paychex, Inc.
Paychex is a leading provider of payroll, human capital management, and insurance solutions servicing small and midsize clients primarily in the United States. The company, established in 1979, services over 730,000 clients and pays over 1 in 12 U.S. private-sector workers. Alongside its traditional payroll services, Paychex offers HCM solutions such as benefits administration and time and attendance software, as well as human resources outsourcing and insurance agency services.
Read more on PAYX →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
